Get started

VYNE Therapeutics Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

VYNE chart

Key stats

Market capitalization
10.89MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−11.04USD
Net income
−36.128MUSD
Revenue
477KUSD
Shares float
3.149M
Beta
1.21

About VYNE Therapeutics Inc.

Sector
Health Technology
CEO
David Domzalski
Headquarters
Bridgewater
Website
vynetherapeutics.com
Employees
12
Founded
2011
ISIN
US92941V3087

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded on October 21, and is headquartered in Bridgewater, NJ.

Ideas

VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA proces
LONG Sec.gov Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the fut
Long
$VYNE Support and ResistanceHC Wainwright & Co. Assumes VYNE Therapeutics at Buy, Announces Price Target of $7 VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammator
Long
My long-term goal on VYNE Since VYNE Therapeutics has enough cash (148m) for 2021 and even into 2022 (possible to turn profitable in 2021), they have a stable cash burn rate. Indicates their financials are strong. Break-even reaches 8500 prescriptions a week / 25 million quarter. Furthermore, with two approved FDA drugs co
Long
5
VYNE: Entering at a support after reverse stock splitVYNE Therapeutics Inc. has caught my attention recently after they announced a reverse stock split at a ratio of 1-for-4. As a novice trader, I am now interested in observing this stock's behavior as it starts trading on a split-adjusted basis, apparently on February 16th. Consequently, I have op
Long
6
My long term thougt of VYNEI recently discovered VYNE - Not sure how, but what made me interested in investing in this stock was their potential to help individuals with severe acne, and based on the technical aspect of bottom formed curve and "break out" from its consolidation period, I felt it was a good thought to get into
Long
VYNE - upTrend is underwayVYNE gapped strongly on 25th January, breaking out of a 10-month resistence @ 2.68 but alas failed to hold on to this level as it then gave up all the gains over the next 1 week to close the gap before attempting to reverse up again. It finally broke and CLOSED above this 2.68 resistence (now tur
Long
12

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers